Srigiridhar Kotamraju

10PUBLICATIONS
5CO-AUTHORS
Metabolic medicineCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMajor global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 13, 2026
Metformin Inhibits Cardiac Fibroblast Differentiation by Promoting Fatty Acid β-Oxidation: Implications for Age-Associated Cardiac Fibrosis.

|Jan 29, 2026
Metadherin with Stromal-Immune Cues Drives CD36-Dependent Lipid Reprogramming and Metastasis in Triple-Negative Breast Cancer: Insights from a Hetero-Spheroid Model.

Soumyadeep Poddar, Shashikanta Sahoo, Yogesh Chandra

|Dec 16, 2025
Doxorubicin Resistance Reprograms Triple-Negative Breast Cancer Cell Metabolism via the Fatty Acid β-Oxidation (FAO)-CD36 Regulatory Circuit: Relevance of Enhanced FAO on Tumor Cell Invasiveness.

Sunita Kumari, Shashikanta Sahoo, Annatta Thomas

|Aug 13, 2024
SIRT1 promotes doxorubicin-induced breast cancer drug resistance and tumor angiogenesis via regulating GSH-mediated redox homeostasis.

Shashikanta Sahoo, Sunita Kumari, Sriravali Pulipaka

|May 17, 2024
Mitochondria targeted esculetin administration improves insulin resistance and hyperglycemia-induced atherosclerosis in db/db mice.

Gajalakshmi Singuru, Sriravali Pulipaka, Altab Shaikh

|Nov 15, 2023
Therapeutic efficacies of mitochondria-targeted esculetin and metformin in the improvement of age-associated atherosclerosis via regulating AMPK activation.

Sriravali Pulipaka, Gajalakshmi Singuru, Shashikanta Sahoo

Pageof 2

Frequent Collaborators

1 joint publications

Altab Shaikh

1 joint publications

Rajkumar Banerjee

1 joint publications

Soumyadeep Poddar

1 joint publications

Biswajit Saha